Ipsen Sues CSPC Pharma to Block Branded Rival to Cancer Drug

Two units of French biopharmaceutical firm Ipsen SA filed a federal lawsuit alleging that an injection to treat advanced pancreatic cancer proposed by Hong Kong-based CSPC Pharmaceutical Group Ltd. infringes a new patent for Ipsen’s Onivyde.

Ipsen Biopharmaceuticals Inc. and Ipsen Biopharm Ltd. allege that the branded injection proposed by CSPC’s Conjupro Biotherapeutics Inc. infringes US Patent No. 12,059,497, which was issued Aug. 13, according to a complaint filed Aug. 23 in the US District Court for the District of New Jersey. Bloomberg Law estimates the patent, which covers Onivyde’s composition and related methods of treatment and manufacture, ...